UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 9, 2019

SECOND SIGHT MEDICAL PRODUCTS, INC.
(Exact Name of Registrant as Specified in Its Charter)

California
(State or Other Jurisdiction of Incorporation)

333-198073	**02-0692322**
(Commission File Number)	(IRS Employer Identification No.)

12744 San Fernando Road, Suite 400
Sylmar, California 91342
(Address of Principal Executive Offices)

(818) 833-5000
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

ITEM 7.01. **REGULATION FD DISCLOSURE**

A copy of a slide presentation that Second Sight Medical Products, Inc. ("Second Sight") intends to use during a presentation at the Digital Medicine and Medtech Showcase 2019, on Wednesday, January 9, 2019 (the "Presentation Materials") is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated by reference herein. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Second Sight may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Second Sight specifically disclaims any obligation to do so. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No. Description

99.1 Second Sight Medical Products, Inc. Investor Presentation dated January 9, 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 9, 2019

SECOND SIGHT MEDICAL PRODUCTS, INC.

/s/ John T. Blake
By: John T. Blake
Chief Financial Officer

Exhibit 99.1


Second Sight Medical Products, Inc.
Digital Medicine and Medtech Showcase
January 9, 2019
SECONDSIGHT
Life In A New Light™
(NASDAQ: EYES)

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," or "planned," "seeks," "may," "will," "expects," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, or that are not otherwise historical facts, are forward-looking statements. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report, on Form 10-K, filed on March 20, 2018, our most recent 10-Q, filed on November 8, 2018 and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in events, conditions, or circumstances on which any such statement is based.

SECONDSIGHT

Breakthrough Technology

Argus® II
Retinal Prosthesis

- First and only FDA approved retinal prosthesis
- ~$200 million and 20+ years invested to develop and commercialize
- Established technology with 293+ implants
- Approved for individuals with advanced retinitis pigmentosa

Next Generation Technology

Orion®
Visual Cortical Prosthesis

- Transformational technology with U.S. human trial initiated in Q12018
- Broad label potential for most causes of blindness including glaucoma, diabetic retinopathy, optic nerve disease and trauma
- Bypasses the retina and optic nerve to directly stimulate the portion of the brain responsible for vision





SECONDSIGHT

Argus® II: Effective Treatment for Blindness

Argus® II is a retinal prosthesis that induces visual perception in individuals with severe to profound retinitis pigmentosa (RP)



Video Link: https://youtu.be/ezVNM05GeUE

SECONDSIGHT

Strategy Centered on Orion®

Execute Orion clinical and R&D programs as our top priority

- U.S. feasibility study at UCLA and Baylor is ongoing with six subjects
- Orion FDA designated **Breakthrough Device** for expedited pathway to commercialization
- R&D to iterate cortical prosthesis and external components in preparation for a pivotal trial

Improve the artificial vision user experience

- Multiple research projects to enhance visual acuity and create a richer user experience
- Examples include object and facial recognition, distance filtering, thermal imaging and eye tracking
- Technologies can be integrated in Argus and Orion platforms

Build and leverage commercial capabilities with capital efficiency

- Focus on Centers of Excellence (COE) and select markets with near-term ROI
- Restructuring completed in Europe to reduce annual commercial spend by approximately $3 million
- Build market development and artificial vision rehab competencies required for Argus and Orion

SECONDSIGHT

Orion®: FDA Breakthrough Device with Potential to Treat Virtually All Forms of Blindness

The addressable market for Orion is potentially over 70,000 individuals in the U.S.; a multi-billion dollar market opportunity



Market outside U.S. expected to be larger

Legally blind due to glaucoma, diabetic retinopathy, optic nerve disease, eye trauma

Addressable market
With bare light or no light perception vision

SECONDSIGHT

Encouraging Early Orion® Feasibility Study Results

Feasibility study at Ronald Reagan UCLA Medical Center and the Baylor College of Medicine

- Five subjects implanted and activated in 1H 2018
- Implanting sixth patient at Baylor College of Medicine in January 2019



Early testing indicates performance comparable to Argus II:

- Observations from rehab sessions indicate some subjects are able to:
  - Locate people in front of them
  - Walk down sidewalk and identify parked cars and driveways
  - Identify cue ball and striped balls on a pool table
  - Sort light from dark laundry
- Four patients cleared for home use
- Field of view appears to be larger than Argus

SECONDSIGHT

Research Technologies to Enhance User Experience

Eye Tracking
Move the implant field of view in conjunction with the movement of the user's eyes

Thermal Imaging
Infrared imaging would allow users to visualize warm objects such as people in a room

Depth-Based Decluttering
Allow users to filter out objects further than a defined distance

Object & Facial Recognition
Receive additional auditory and/or haptic information integrated with their artificial vision

Research projects have potential to benefit Argus and Orion users

Orion® Leverages our Commercial Experience & Argus II Technology

Centers of Excellence (COE) model and artificial vision rehabilitation

- Centers of Excellence model to build regional artificial vision centers for Argus and Orion
- Best practices development and pioneered post-surgical rehabilitation to improve patient satisfaction and outcomes for all artificial vision patients

Effective patient outreach & screening with U.S. patient database

- Effective patient outreach programs and a multi-step patient qualification process applicable to Argus and Orion
- Large and growing U.S. database that includes potential Argus and Orion patients

Market access & reimbursement expertise benefits Orion

- Argus is an established therapy in over a dozen markets globally
- Achieved highest CMS outpatient reimbursement rate in U.S. at $152.5k for 2019
- Conducting clinical studies via Forfait Innovation (France) and Commissioning Through Evaluation (England) programs for national reimbursement

Orion leverages Argus II technology platform

- Established technology with 10 years+ proven implant durability
- Proprietary algorithms for artificial vision

SECONDSIGHT

Innovative Pipeline Extends our Leadership Position



SECONDSIGHT

Key Drivers of Shareholder Value through 2019

Orion

Release interim data from first six subjects of feasibility trial

Agreement on pivotal and post-market trial designs via the FDA's Breakthrough Device Program



Argus II

Prioritize Argus activities that maximize ROI or have strategic value to Orion

Submit regulatory filings for Argus 2s next-generation externals and execute commercial launch

SECONDSIGHT

Select Financial Data

(USD $ in thousands)	FY 2018	FY 2017	FY 2016
Implants	***69***	***75***	***42***
Revenue	$6,500-$6,949[1]	$7,964	$3,985
Gross Profit (Loss)	Pending	$2,847	$(6,091)
Net Loss		$(28,516)	$(33,179)
Non-GAAP Adjusted Net Loss[1]		$(27,576)	$(24,812)

1) Non-GAAP adjusted net loss excludes non-cash expenses including stock-based compensation and reserve for excess inventory.

(USD $ in thousands)	December 31, 2018	December 31, 2017
Cash and cash equivalents	$4,466	$7,839
Debt	$0	$0

1 – Estimate provided pending completion of annual GAAP accounting close and audit

SECONDSIGHT

13

Second Sight Investment Highlights

Orion is a large market opportunity that is more than 50x the current RP market

- Potential to treat nearly all forms of blindness including diabetic retinopathy, glaucoma, optic nerve disease and eye injury
- Feasibility study at UCLA and Baylor underway with good early results and interim data in next six months
- FDA Breakthrough Device designation provides expedited regulatory and clinical pathway

Orion leverages Argus II

- Orion leverages Argus technology including implantable array, externals and proprietary software / algorithms for creating artificial vision
- Orion also leverages reimbursement success, patient outreach and screening expertise as well as artificial vision rehabilitation competencies

Future technologies under development beneficial to Argus II and Orion

- Eye-tracking, thermal imaging and depth-based decluttering provide improved or more useful vision
- Object recognition and facial recognition create enhanced user experience

Argus II business focused on capital efficiency and strategic benefit

- Commercial competencies and R&D efforts such as Argus 2s next-gen externals that benefit Orion are prioritized
- ROI and cost structure improvements important when evaluating markets or expansion

SECONDSIGHT

Contacts

Second Sight Medical Products, Inc.
12744 San Fernando Road
Suite 400
Sylmar, CA 91342
Main: 818-833-5000
www.secondsight.com

Will McGuire
President & CEO
Direct: 818-833-5040
wmcguire@secondsight.com

Retail Investor Relations
Greg Falesnik
Managing Director
MZ North America
Direct: 949-385-6449
Greg.Falesnik@mzgroup.us

Institutional Investor Relations
Lisa Wilson
President
In-Site Communications, Inc.
Direct: 212-452-2793
lwilson@insitecony.com

SECONDSIGHT